Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Douglas MW, Johnson RW, Cunningham AL. Tolerability of treatments for postherpetic neuralgia. Drug Saf 2004; 27(15): 1217–33
Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994 Mar 31; 330(13): 896–900
Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996 Sep 1; 125(5): 376–83
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 Jun 2; 352(22): 2271–84
Levin MJ, Murray M, Rotbart HA, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992 Aug; 166(2): 253–9
Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002 Jul 4; 347(1): 26–34
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cunningham, A.L. Zoster Vaccine Live (Oka/Merck). Drugs Aging 23, 532 (2006). https://doi.org/10.2165/00002512-200623060-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200623060-00008